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Somatic mutations in Isocitrate Dehydrogenase 1 (IDH1) are frequent in low 
grade and progressive gliomas. IDH1 mutant tumors are phenotypically characterized by 
the increased production of 2-hydroxyglutarate (2-HG) from α-ketoglutarate. 2-HG is an 
“oncometabolite” that competitively inhibits α-KG dependent dioxygenases. The 
inhibition of these dioxygenases causes widespread cellular changes including abnormal 
hypermethylation of genomic DNA and suppression of cellular differentiation. Recent 
investigations of malignant gliomas have identified additional genetic and chromosomal 
abnormalities that cluster with IDH1 mutations into two molecularly distinct subgroups. 
The astrocytic subgroup is defined by frequent mutations in ATRX, TP53 and displays 
alternative lengthening of telomeres. The second subgroup with oligodendrocytic 
morphology has frequent mutations in CIC or FUBP1, and is linked to co-deletion of the 
1p/19q arms. These mutations reflect the development of two distinct molecular 
pathways representing the majority of IDH1 mutant gliomas. Unfortunately, due to the 
scarcity of endogenously derived IDH1 mutant models, opportunities to evaluate 
therapies targeted to the mutation or its consequences have been limited.  
Here we report the generation of an endogenous IDH1 mutant anaplastic 
astrocytoma model. This novel tumor model expresses the IDH1 (R132H) mutant 
protein, grows rapidly in vivo, produces 2-HG, exhibits DNA hypermethylation and 
harbors concurrent mutations in TP53, CDKN2A and ATRX.  Furthermore, this model has 
a similar histopathology as the original patient tumor, and exhibits an alternative 
lengthening of telomeres phenotype.  
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Using this in vivo model, we have demonstrated the preclinical efficacy and 
mechanism of action of the FDA approved demethylating drug 5-azacytidine. Long term 
administration of 5-azacytidine resulted in reduction of DNA methylation of promoter 
loci, induction of glial differentiation, reduction of cell proliferation and a significant 
reduction in tumor growth. Tumors regressed by 14 weeks and subsequently showed no 
signs of re-growth at 7 weeks despite discontinuation of therapy.  These results suggest 
that demethylating agents might be useful for the clinical management of patients with 
IDH-mutant gliomas.  
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METABOLIC AND EPIGENETIC ALTERATIONS IN IDH1/2 MUTANT GLIOMAS 
 
Gliomas are a collection of nervous system tumors arising from glial cells such as 
astrocytes and oligodendroglia. The most deadly and aggressive of these gliomas is the 
grade IV astrocytomas, or glioblastoma multiforme (GBM). To better understand the 
genetic basis of GBM, 22 GBM genomes were sequenced.  This study quantified the 
frequency of previously known mutations (e.g. TP53, EGFRvIII, PI3KCA) and led to the 
discovery of acquired mutations in IDH1, that were not previously known or associated 
with cancer [1]. Subsequent studies discovered mutations in IDH2, the mitochondrial 
homologue of IDH1 [2]. There has been progress understanding the role of IDH1/2 
mutation in tumor formation and maintenance and recent findings have implicated altered 
enzymatic activity producing metabolic changes that ultimately disrupt normal 
epigenetics as likely contributing mechanisms. 
 
Metabolism and Cancer 
Associations between metabolism and cancer were first documented in the 1920’s 
by Otto von Warburg. Warburg demonstrated that cancer cells exhibited increased rates 
of glycolysis and decreased dependence on oxidative phosphorylation, despite the 
presence of sufficient oxygen [3, 4]. Recently, the goals of understanding and 
therapeutically exploiting altered metabolism in cancer cells have received renewed 
interest.  Oncogenes and tumor suppressors (e.g. MYC, TP53, PI3KCA, etc.) contribute to 
the altered regulation of metabolism in tumors, and the unmutated versions of these genes 
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play roles in normal cell metabolism [5-7]. However, relatively few mutations in genes 
encoding metabolic enzymes are known to contribute to oncogenesis.  Known mutations 
include succinate dehydrogenase (SDH), fumarate dehydrogenase (FH), and IDH1/2 [1, 
6-8]. SDH and FH mutations are associated with familial cancer syndromes and lead to 
enzymatic inactivation, with subsequent accumulation of their respective substrates, 
succinate and fumarate.  Accumulation of these metabolites contributes to tumorigenesis 
by stabilizing HIF-1α in the presence of normoxic conditions through inhibition of prolyl 
hydroxylase domain 2 (PHD2).  PHD2 utilizes O2 and α-ketoglutarate (α-KG) to 
hydroxylate HIF-1α, leading to its degradation.  Inhibition of PHD2 in the presence of 
sufficient oxygen leads to increased HIF-1α and promotes tumorigenesis through 
increased glycolysis and angiogenesis [6-10].  
 
IDH1/2 mutation frequency  
GBMs develop de novo (primary) or develop from lower grade gliomas 
(secondary).  Mutations in IDH1/2 occur in up to 70% of low grade gliomas and 
secondary GBMs [2] and in up to 12% of all primary GBMs [1].  IDH1 and IDH2 
mutations also occur in 16% of acute myelogenous leukemia (AML) and up to 33% in 
AMLs with normal karyotypes [11], 56% of central and periosteal cartilaginous tumors 
[12], and 10-20% of cholangiocarcinomas as well as several rare cases of paraganglioma, 
colon cancer, prostate cancer, and lung cancer [13-17].  
The role of an IDH1 or IDH2 mutation as an indicator of progression and survival 
is not well established.  It has been reported that IDH1/2 mutation results in decreased 
prognosis for AML [18-20] and  increased prognosis for both low grade gliomas (65 
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months for mutant IDH1/2 versus 38 months for wild type) and secondary GBMs (31 
months for mutant IDH1/2 versus 15 months for wild type) [2]. However, it is possible 
that IDH1/2 mutant tumors may become clinically apparent earlier than IDH1/2 wild type 
tumors, resulting in a misleading association with increased survival.  
 
IDH1 enzymatic function and consequences of mutation  
Wild type IDH catalyzes the oxidative decarboxylation of isocitrate to α-KG with 
simultaneous reduction of NADP+ [21-23]. IDH1 mutations affect a single amino acid 
residue, R132 [1, 2], whereas IDH2 mutations affect two residues, R140 or R172 (the 
functional equivalent of R132 in IDH1) [11]. The most common IDH1 mutation in 
tumors is the R132H missense mutation [2]. These recurrent IDH1/2 mutations result in 
two enzymatic changes: decreased wild type IDH function (oxidative decarboxylation of 
isocitrate to α-KG with simultaneous reduction of NADP+) [21-23] and gain of a new 
enzymatic capability [(reduction of α-KG to D-2-hydroxyglutarate (2-HG)] with 
simultaneous oxidation of NADPH [21, 22] (Figure 1.1).  At the biochemical level, 
changes in the active site of mutant IDH1/2 enzymes prime the enzyme to produce 2-HG 
by increasing its affinity for α-KG and shifting the conformation of the enzyme to favor 











Figure 1.1. Epigenetic and metabolic alterations in IDH1/2 mutant tumor cells. 
IDH1/2 mutant enzyme activity results in high intracellular D-2-HG levels and alterations 
in glutamine metabolism, citrate and acetyl-coA levels, and fatty acid metabolism. D-2-
HG is also able to compete with α-KG for binding to histone demethylases and DNA 




IDH1/2 mutations, 2-HG & metabolic disorders  
2-HG accumulation is a biochemical hallmark of IDH1/2 mutant tumors. Cells 
expressing wild type IDH1/2 have low levels of 2-HG, a normal byproduct of L-
hydroxylysine breakdown that has no known function within the cell.  2-HG is normally 
removed from the cell through conversion to α-KG by D-2-hydroxyglutarate 
dehydrogenase.  Interestingly, D-2-HG and its stereoisomer L-2-HG accumulate in the 
metabolic disorders D-2 or L-2 hydroxyglutaric aciduria (D-2 or L-2-HGA), respectively 
[25-28]. 
L-2-HGA results from inactivation of L-2-hydroxyglutaric dehydrogenase [27], 
while D-2-HGA results from inactivation of D-2-hydroxyglutarate dehydrogenase or 
IDH2 mutations [25, 27, 29]. Inherited IDH2 mutations that cause D-2-HGA disease are 
identical to those found in gliomas or AML.  Interestingly, L-2-HGA patients have been 
documented to develop gliomas, [29-33] however no cases of glioma have been 
documented in D-2-HGA patients, despite D-2-HG accumulation [25, 27, 28, 34]. These 
results may suggest that increased D-2-HG levels alone are not sufficient to cause 
tumorigenesis. 
 
IDH1/2 mutations & Tumorigenesis 
IDH1/2 mutations are predicted to have a very high probability of being driver 
mutations using CHASM (Cancer-Specific High-Throughput Analysis of Somatic 
Mutations) [35], which predicts the impact of the mutation on the protein, and attempts to 
determine the similarity of alteration with known cancer drivers. IDH1/2 mutations occur 
in grade II progressive gliomas, prior to their progression to higher grade and 
 5 
accumulation of the full complement of mutations found in glioblastoma . The frequency 
of these mutations does not increase with tumor grade, suggesting that these mutations 
are likely involved in the initial tumor development [2, 36]. Initially, studies suggested 
that IDH1/2 mutations contribute to tumorigenesis through stabilization of HIF-1α, 
similar to SDH and FH mutations [23].  These studies suggested α-KG levels were 
significantly decreased in IDH1/2 mutant cells and that this decrease lead to inactivation 
of PHD2 and stabilization of HIF-1α [23]. However, subsequent studies have found that 
α-KG levels are not significantly altered in IDH1/2 mutant cells, despite increased 
cellular demand for D-2-HG production [21, 22, 37-39]. Additionally, studies in AML 
and glioma with IDH1/2 mutations did not detect increased stabilization of HIF-1α [36, 
40]. Therefore, while HIF-1α stabilization could in theory could contribute to 
tumorigenesis, other pathways appear to play a larger role (Figure 1.1).   
In cells that harbor IDH1/2 mutations, intracellular 2-HG levels can reach up to 
10 mM [21, 22, 41]. 2-HG and α-KG are similar in structure, and recent studies have 
shown that 2-HG serves as competitive inhibitor of enzymes that utilize α-KG as a co-














More than 60 enzymes utilize α-KG as a co-factor [43] and 2-HG can 
competitively inhibit many of these enzymes.  For example, 2-HG outcompetes α-KG for 
binding to several classes of histone demethylases, PHD2 and the TET family of 5-
methylcytosine hydroxylases [40, 42]. Crystallographic studies confirm that 2-HG fits 
into binding sites for α-KG in dual-specificity histone demethylase KIAA1718 
(KDM7A), factor inhibiting hypoxia-inducible factor (FIH) and jumonji domain 
containing protein 2A (JMJD2A) [40, 42]. High intracellular levels of 2-HG in IDH1/2 
mutant tumors are likely sufficient for potent enzymatic inhibition and suggest a likely 
mechanism by which IDH1/2 mutations contribute to tumorigenesis [40].  
Interestingly, mutant IDH1/2 cases in AML have a characteristic hypermethylated 
phenotype which may result from inhibition of TET2 by 2-HG [44]. TET2 catalyzes the 
conversion of methylcytosine to 5-hydroxymethylcytosine and is mutated in 
approximately 24% of secondary AMLs.  TET2 mutations result in a hypermethylated 
phenotype highly similar to that seen in mutant IDH1/2 AMLs, although the two 
mutations are mutually exclusive [44]. Differentially methylated genes in IDH1 mutant 
gliomas include processes known to contribute to tumor progression as well as several 
metabolic pathways (Table 1).  In gliomas, a hypermethylated phenotype has also been 
identified, the glioma-CpG island methylator phenotype (G-CIMP) which correlates 
tightly with IDH1 mutations. Recent studies have shown that IDH1 mutations alone are 
capable of inducing the G-CIMP phenotype as well as decreasing levels of 5-
hydroxymethylcytosine in human astrocytes. Collectively, the data suggests that IDH1 
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mutations contribute to tumorigenesis by inducing wide scale epigenetic remodeling 






Hypomethylated pathways Hypermethylated pathways
Methane metabolism Protein kinase A signaling
Pregnane X receptor/ Retinoid X receptor 
activation Angiopoetin signaling
Retinol metabolism Ras related nuclear protein signaling
Phenylalanine metabolism Retinol transport 
Starch and sucrose metabolism Cell cycle regulation




Androgen and estrogen metabolism Fatty acid binding
Increased Decreased 
Transcriptional regulation Polysaccharide binding
Nucleic acid synthesis Heparin binding
Metabolic processes Glucosaminoglycan binding
Cadherin based cell adhesion Collagen









































   
   
   
   
   
   











































IDH1/2 mutations and metabolic alterations 
Transcriptional analysis of aberrantly methylated genes in primary G-CIMP 
tumors by Noushmehr, et al. found significant upregulation in genes involved in 
metabolic processes including carbohydrate metabolism, oxidative stress response, and 
nucleic acid synthesis (Table 1.1) [46]. Pathways transcriptionally repressed in G-CIMP 
tumors include those involved in tumor invasion, extracellular matrix remodeling, 
retinoic acid signaling and mesenchymal markers (Table 1.1) [46]. Subsequent studies 
using large sets of IDH1 mutated low grade glioma samples as well as human astrocytes 
expressing IDH1 mutant protein show that the IDH1 mutation leads to methylation 
changes in genes regulating cellular differentiation, particularly the polycomb complex 2 
(PRC2)-targeted loci [45]. Although the precise mechanism for these changes are not yet 
known, it is believed that 2-HG produced by IDH1/2 mutations leads to global epigenetic 
alterations leading to changes in the expression of genes regulating cellular 
differentiation and metabolism. 
Numerous metabolic changes have been confirmed by metabolomics studies on 
IDH1/2 mutant cells [38, 39]. Reitman et al. identified changes resulting from expression 
of mutant IDH1/2 or treatment with 2-HG (Table 1.1) [38].  Some metabolic alterations 
were found under both conditions; however, approximately half of the observed changes 
in IDH1/2 mutant expressing cells could not be replicated by treatment with exogenous 
2-HG.  Most notably, decreases in glutamate levels and metabolites whose synthesis 
involves glutamate were not replicated by 2-HG treatment.  Therefore, these changes are 
a direct result of the enzymatic activity of IDH1/2 mutant enzymes.   
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One such metabolic alteration is the reduction of the neuropeptide N-acetyl-
aspartyl glutamate (NAAG) and its precursor N-acetylated aspartic acid (NAA) in 
IDH1/2 mutant cells and tumors by up to 50-fold [38]. NAAG is synthesized from NAA 
and glutamate by NAAG synthase and functions in glutamatergic pathways of the brain 
[47]. Reitman et al. found that even when NAA levels are replenished, NAAG levels are 
not fully restored indicating that the glutamate necessary for generation of NAAG may be 
shuttled for production of α-KG and subsequently 2-HG. In either case, the consequences 
of lowered intracellular NAAG levels on tumor formation and maintenance are unknown 
and warrant further study.   
Mutant IDH1/2 produce 2-HG from glutamine derived α-KG, resulting in 
increased flux through this pathway [22]. Therefore, cells expressing mutant IDH1/2 may 
be more dependent upon this pathway for growth and survival. In support of this 
hypothesis, inhibition of α-KG synthesis from glutamine led to a 15-20% decrease in 
growth for cells expressing mutant IDH1 [39]. To further characterize this growth 
inhibition, metabolite levels were evaluated following treatment with BPTES, a small 
molecule inhibitor of glutamine, the first enzyme in the synthesis of α-KG from 
glutamine. Glutaminase inhibition lowered glutamate and α-KG levels in IDH1 wild type 
and mutant cells but 2-HG levels were not reduced, indicating the presence of a 
compensatory mechanism [39]. 
Changes in other metabolites following BPTES treatment also supported this 
hypothesis. These metabolic changes, including increases in glycolytic intermediates and 
decreased levels of TCA cycle intermediates, were seen in both wild type and mutant 
IDH1 expressing cells treated with BPTES [39]. Consequently, α-KG might be produced 
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or diverted away from the TCA cycle to compensate for inhibition of α-KG produced 
from glutaminase. In light of these results, metabolic inhibition has been suggested as a 
potential approach for selective targeting of IDH1/2 mutant tumors. However our 
subsequent preclinical studies indicated that glutaminase inhibition alone would not 
likely be sufficient as a therapeutic strategy due to compensatory routes of α-KG 
production. Inhibition of these compensatory routes would likely be required for an 
effective therapeutic response. 
Changes in fatty acid metabolism may also result from the expression of IDH1/2 
mutants. Mutant IDH1-expressing cells exhibit decreased levels of citrate compared with 
wild type expressing IDH1 cells, as well as increases in acetyl-CoA and triglyceride and 
phospholipid precursors [38, 39]. The combination of decreased citrate and increased 
lipid precursors may indicate that IDH1 mutant expressing cells shuttle citrate out of the 
TCA cycle to produce lipids required for cell growth.  Increases in fatty acid/lipid 
synthesis are a common characteristic of many cancers, including gliomas [48], and it is 
possible IDH1/2 mutation may contribute to this phenotype. In addition, mutant IDH1 
may lead to decreased fatty acid oxidation in two ways: reducing available cofactors for 
peroxisomal β-oxidation and by decreasing carnitine biosynthesis for mitochondrial fatty 
acid transport.  
Oxidation of α-phytanic acids and β-oxidation of certain fatty acids within 
peroxisomes requires both NADPH and α-KG, products of wild type IDH1 activity.  
IDH1 has been shown to be the sole source of these molecules within the peroxisomes 
[49].  Mutant IDH1 has decreased ability to produce NADPH and α-KG suggesting that 
mutation of IDH1 may lead to decreased levels of these substrates within peroxisomes 
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and potentially decreased rates of fatty acid oxidation.   Chowdury et al. demonstrated 
that high levels of 2-HG can inhibit γ-butyrobetaine hydroxylase 1, the last enzymatic 
step in carnitine biosynthesis [40].  Carnitine is required for activation and transport of 
fatty acids into the mitochondria to undergo β-oxidation.  Consistent with this finding, 
levels of propionylcarnitine (a carnitine ester which sustains endogenous carnitine pools) 
were decreased in IDH1/2 mutant and 2-HG treated cells [38]. Therefore, IDH1/2 
mutations may contribute to tumorigenesis by priming cells for growth by increasing 
fatty acid synthesis and reducing oxidation of certain fatty acids.           
 
IDH1/2 mutations and anti-cancer metabolism-based therapy  
The discovery of mutations in IDH1 and IDH2 in gliomas has profound 
implications for the understanding and treatment of these cancers. Studies in AML have 
shown that 2-HG can be detected in serum, and increased 2-HG levels correlate with 
IDH1/2 mutational status [21, 41]. Elevated 2-HG levels could therefore serve as a 
biomarker to identify IDH1/2 mutational status or monitor tumor growth or treatment 
efficacy. The use of 2-HG as a biomarker in gliomas is currently under investigation; 
however, detection may be technically challenging as the degree of 2-HG diffusion from 
solid glial tumors into serum, cerebrospinal fluid, or urine is unknown.  Alternatively, 2-
HG can be detected by magnetic resonance spectroscopy (MRS), allowing for non-
invasive monitoring of tumor progression or classification of IDH1/2 mutational status 
[50].  
The distinct metabolic alterations resulting from IDH1/2 mutations reveal a 
potential opportunity for therapeutic intervention.  One potential strategy for treatment of 
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IDH1/2 mutant tumors is inhibition of α-KG synthesis from glutamine.  Studies from our 
group have demonstrated that inhibition of this pathway can specifically slow the growth 
of mutant IDH1 expressing cells [39].  However, compensatory mechanisms and the 
mutational background of glioma cells suggest that multiple metabolic components may 
need to be targeted for the development of a successful therapeutic strategy. Further 
investigation of the role of IDH1/2 and 2-HG on the epigenome and the metabolome will 






DEVELOPMENT AND CHARACTERIZATION OF A NOVEL MODEL OF A 
PATIENT-DERIVED IDH1 MUTANT GLIOMA WITH ALTERNATIVE 
LENGTHENING OF TELOMERES 
Introduction 
 
 Since the identification of IDH1 as an oncogene in 2008, mutations have been 
found in the majority of grade II-III gliomas and secondary glioblastoma multiforme. 
Driver mutations in IDH1 affect a single residue, R132, which is located in the substrate 
binding pocket. Mutations in this residue enhance the conversion of α-ketoglutarate (α-
KG) to D-2-hydroxyglutarate (2-HG). Though normally present at very low levels in the 
cell, intracellular 2-HG concentrations can be increased up to 10-30 mM in IDH1 mutant 
tumors [22, 41, 51]. Owing to the close structural similarity between the metabolites, 2-
HG is believed to promote tumorigenesis by competitively inhibiting α-KG dependent 
dioxygenases including the Jumonji C-domain containing histone demethylases and the 
TET family of DNA methylcytosine dioxygenases, believed to function in DNA 
demethylation [42].  Ultimately, continued exposure to 2-HG results in widespread 
cellular changes, including characteristic hypermethylation of genomic DNA, 
suppression of cellular differentiation and metabolic deficits [39, 45, 46, 52].  
 Although our understanding of IDH1 mutated gliomas grows, the development of 
relevant models remains a challenge. Patient-derived IDH1 mutant tumors have been 
difficult to culture and published xenografts are restricted to oligodendroglioma and 
oligoastrocytoma backgrounds [53, 54]. The development and molecular characterization 
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of additional endogenous IDH1 mutant astrocytoma models is important for preclinical 
testing molecular based therapies which target progressive gliomas.  
Here we report the generation of an endogenous patient derived IDH1-mutant 
anaplastic astrocytoma in vivo model, derived from a patient tumor with driver mutations 
in TP53, CDKN2A and ATRX.  Although cells from this tumor do not proliferate in vitro, 
the in vivo model faithfully resembles the patient tumor and robustly expresses the IDH1 
(R132H) mutant protein in both the flank and orthotopic sites. Additionally, the model 
exhibits a phenotype characteristic of an anaplastic astrocytoma characteristic including 
robust production of 2-HG, genome hypermethylation and alternative lengthening of 
telomere (ALT).  
  
 17 
Material and Methods 
Xenograft establishment  
 Tumor tissue was obtained during the resection of an anaplastic astrocytoma 
(WHO grade III) from a male patient. The tissue was mechanically disassociated, mixed 
with an equal volume of growth factor–reduced Matrigel (BD Biosciences, CA), and 
injected subcutaneously into the flanks of athymic nude mice (0.2cc/flank). All animal 
protocols and procedures were performed in accordance with the Johns Hopkins Animal 
Care and Use Committee guidelines. The mice were housed in standard facilities and 
given free access to Baltimore City water and chow. Animals were monitored frequently 
for signs of tumor growth. Xenografts were passaged in a similar fashion. Cross-sectional 
samples were obtained at each passage and either snap frozen or fixed in formalin. The 
samples were then embedded in paraffin and stained by H&E or used for 
immunohistochemistry. The IDH1 (R132H) mutation was validated by direct sequencing 
at every passage.  
For orthotopic xenografts, flank xenografts were resected and enzymatically 
disassociated using a 2:1 ratio of collagenase (10mg/mL, Invitrogen, NY) and 
hyaluronidase (1000 units/mL, Sigma, MO). Cell number and viability was assessed 
using Trypan blue exclusion. For intracranial implantations, 500,000 cells were 
stereotactically implanted into the right frontal cortex of 4-6 week old female athymic 
nude mice (NCI-Frederick) as previously described [55]. Mice were sacrificed upon 
showing symptoms of distress and the brains removed and formalin fixed for subsequent 
gross pathological examination of tumor formation and immunohistochemistry.  
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Sequencing of IDH1  
Genomic DNA was isolated from patient tissue and flank xenografts using the 
DNeasy Blood and Tissue Kit (Qiagen, CA) according to the manufacturer’s instructions. 
PCR and sequencing was conducted as previously described [39] Briefly, 60 ng of 
genomic DNA was added to a standard PCR reaction to amplify a portion of exon 4 of 
IDH1 (forward 5’- GTAAAACGACGGCCAGTTGAGCTCTATATGCCATCACTGC 
3’, reverse 5’- CAATTTCATACCTTGCTTAATGGG-3’) . The PCR product was 
purified using the QIAquick Gel Extraction Kit (Qiagen, CA) and submitted for 
sequencing (Genewiz, NJ) using targeted primers (forward 5’- 
CGGTCTTCAGAGAAGCCATT-3’, and reverse 5’-
GCAAAATCACATTATTGCCAAC-3’)   
 
Histology and Immunohistochemistry 
All histopathological and immunohistochemical analyses were performed using 
tissue fixed in 10% formalin and embedded in paraffin. Tissue was obtained from patient 
samples after appropriate approval was obtained from the Johns Hopkins University 
Institutional Review Board. Paraffin-embedded sections were cut at 5 microns, 
deparaffinized, and stained with either hematoxylin and eosin (H&E) or 
immunohistochemical stains as specified. Heat-induced epiotope retrieval was performed 
for 36 minutes at 98°C in EDTA buffer (pH 9.0). Immunohistochemical staining was 
performed using antibodies specific for IDH1 (R132H) (dilution 1:50, Dianova, clone 
H09, Germany) and visualized using the ultraView DAB detection system (Ventana 
Medical Systems, AZ).  
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LC/MS 
 2-hydroxyglutarate levels were analyzed from snap frozen flank xenograft 
samples. Prior to extraction, frozen samples were thawed in a water bath at ambient 
temperature.  Tissue homogenates were prepared at a concentration of 200 mg/mL in 
methanol.  A 10 µL aliquot of homogenized tissue was added to a borosilicate glass test 
tube (13x100 mm) containing 10 µL of acetonitrile solution and 2-phosphonomethyl 
pentanedioic acid (1 mg/mL), which was used as the internal standard.  The tube was 
mixed vigorously and evaporated under nitrogen gas at 4°C until completely dried. After 
the samples were dried, 100 µl of acetonitrile and 100 µL of N-tert-Butyldimethysilyl-N-
methyltrifluoro-acetamide were added sequentially. The tubes were incubated at 80°C for 
1 hour then diluted 1:10 with acetonitrile.  100 µl of the top layer was transferred to a 
250-µL polypropylene autosampler vial sealed with a Teflon crimp cap. 10 µL of each 
sample was injected onto the LC/MS/MS for quantitative analysis using a temperature-
controlled autosampling device operating at 10°C. Chromatographic analysis was 
performed using an ACQuity TM UItra Performance LC (Waters, MA).  Separation of the 
analyte from potentially interfering material was achieved at ambient temperature using 
X-Terra® RP18 column (20 x 2.1 mm, Waters, MA) packed with a 3.5 µm RP18 material 
(Milford, MA). The mobile phase used for the chromatographic separation was composed 
of acetonitrile with 0.1% formic acid and 2mM ammonium acetate in water (80:20, v/v) 
and delivered using an isocratic flow rate of 0.3 mL/minute.  The column effluent was 
monitored using a QTRAP R 5500 mass spectrometer (AB SCIEX, MA). The instrument 
was equipped with an electrospray interface, operated in a positive mode and controlled 
by the Analyst 1.5.1 software. The mass spectrometry was programmed to monitor the 
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following MRM’s 491.0  359 for 2HG and 683.0  551.4 for the IS. Samples were 
quantified over the assay range of 0.02 to 2 µg/mL. The standard curve of ratio response 
(analyte peak area/IS peak area) vs. concentration was plotted using linear regression 
with 1/x weighting for the data analyzed. 
 
Whole Exome Sequencing 
Genomic DNA was isolated from normal human whole blood and flank xenograft 
tissue as described above. gDNA fragmentation was performed with the Bioruptor 
(Diagenode, NJ), and size selection at 200 bp - 300 bp was carried out. The exomes of 
gDNA were captured using the SureSelect All Exon 50Mb Target Enrichment kit 
(Agilent, CA) according to the manufacturer's instructions. DNA captured was run on the 
HiSeq2000 platform (Illumina, CA) with version 5 chemistry and version 4 flow cells, 
according to the manufacturer's instructions, to generate 100-base paired-end reads. 
Reads in fastq format were initially processed with GATK to remove Illumina adaptor 
sequences and Phred-scaled base qualities of ≤10 (-QT 10). After GATK trimming step, 
reads were mapped using the Burrows-Wheeler Aligner (version 0.6.1) with a –q 20 
setting for read trimming, which removes the 3′ portion of reads from an alignment if it is 
below the quality threshold specified. The alignments (sai files) were used to generate 
SAM (Sequence Alignment/Map) paired-end read files. All SAM files were converted to 
BAM files then sorted BAM files with Samtools (version 0.1.18). PCR and optical 
duplicates and multiple reads likely to have been read from a single cluster on the flow-
cell image were marked with Picard tools. Regions that needed to be realigned were 
identified using the GATK Realigner Target Creator. The reads covering localized indels 
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were realigned, and quality values were recalibrated using GATK. The GATK was also 
used to locate, filter and annotate variants. Somatic changes including point mutations 
and small indels were called based on comparison between the xenograft and control 
blood. All predicted deleterious mutations not existing in dbSNP were counted. 
Mean exonic coverage was calculated for all exonic baits in xenograft and control 
samples by GATK. The mean exonic coverage was subsequently normalized by average 
whole exome coverage of the sample. Individual case vs. control log2 ratios were then 
calculated for all the exons in the data set and plotted. The presence of copy-number 
alterations was detected using a combined approach involving a set of statistical 
Wilcoxon signed-rank tests performed on a 500,000 bp sliding windows along the 
genome. Amplifications were defined as greater than 4 copies of the gene (case vs. 
control log2 ratio greater than 8).  
 
Telomere-specific FISH and microscopy 
Telomere-specific FISH was conducted as previously described [56, 57]  Briefly, 
deparaffinized slides were hydrated, steamed for 20 minutes in citrate buffer (Vector 
Laboratories, GA), dehydrated, and  hybridized with a Cy3-labeled peptide nucleic acid 
(PNA) probe complementary to the mammalian telomere repeat sequence ([N-terminus to 
C-terminus] CCCTAACCCTAACCCTAA). As a positive control for hybridization 
efficiency, a FITC-labeled PNA probe having specificity for human centromeric DNA 
repeats (ATTCGTTGGAAACGGGA; CENP-B binding sequence) was also included in 
the hybridization solution [58]. Slides were imaged with a Nikon 50i epifluorescence 
microscope equipped with X-Cite series 120 illuminator (EXFO Photonics Solutions Inc., 
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Ontario, CA) and appropriate fluorescence excitation/emission filters. Grayscale images 
were captured for using Nikon NIS-Elements software and an attached 
PhotometricsCoolsnapEZ digital camera, pseudo-colored and merged. The telomerase-
independent alternative lengthening of telomeres (ALT) phenotype was confirmed by the 
presence of abnormally large and intense intra-nuclear telomere FISH signals; a hallmark 
of cells utilizing the ALT pathway.  Such foci are not observed in normal cells, nor are 




Results and Discussion 
Establishment and serial passage of an IDH1 (R132H) anaplastic astrocytoma 
model 
Tumor was obtained from the resection of a recurrent anaplastic astrocytoma 
(WHO grade III) from a male patient with a history of glioma, presenting with a large 
right temporal lobe tumor. The patient had been diagnosed with a low grade astrocytoma 
(WHO grade II) twelve years prior, which had been surgically resected at that time. The 
recurrent tumor was found to have a high degree of anaplasia but lacked areas of necrosis 
and vascular proliferation. Direct sequencing of IDH1 exon 4 demonstrated that the 
tumor harbored a heterozygous G395A (R132H) mutation (Figure 2.1C). This alteration 
was validated by detection of the mutant protein by immunohistochemistry (Figure 2.1B). 
Tumor tissue was implanted subcutaneously into athymic nude mice. Additionally, 
neurosphere culture was attempted in multiple media conditions including serum-free 
media containing hFGF and hEGF. Although the tissue was not amenable to in vitro 
culture, a first generation tumor arose in the mouse approximately one month after 
implantation as a large, localized subcutaneous mass. Direct sequencing of the xenograft 
tissue revealed retention of the IDH1 (G395A) mutation but a loss of the wild type allele 
(Figure 2.1C). Immunohistochemistry demonstrated strong IDH1 (R132H) expression 
throughout the xenografted tissue (Figure 2.1B). All subsequent serial xenograft passages 
have retained the hemizygous IDH1 (R132H) mutation and exhibit robust expression of 
the mutant protein.  
 
Xenografts show histopathological similarity and diffuse growth pattern 
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Histopathological analysis of H&E samples obtained from the primary tumor 
sample and tumor-derived xenograft tissue show that both the flank and orthotopic 
xenografts maintain histopathological similarity to the primary tumor and also maintain 
morphology characteristic to an anaplastic astrocytoma (Figure 2.1B, Figure 2.2). The 
primary tumor was a cellular infiltrating astrocytoma with scattered gemistocytic cells as 
well as rare tumor giant cells. Scattered mitotic figures were identified consistent with the 
diagnosis of an anaplastic astrocytoma (Figure 2.2, inset). Immunostaining for mutant 
IDH1 was strongly and diffusely positive. Initial flank xenografts maintained many of the 
features of the primary tumor including a typical astrocytic morphology as well as 
scattered tumor giant cells, mixed with vascular, stromal, and skeletal muscle elements 
characteristic of this anatomical site (Figure 2.1).  
Intracranial implantation of the tumor resulted in infiltrative growth throughout 
the cortex and deep grey matter structures (Figure 2.2). In some xenografts tumors, cells 
infiltrated through the corpus collosum to the contralateral hemisphere, a characteristic 
finding of infiltrating gliomas. Some xenografts grew within the leptomeninges and 
ventricles. As in the primary tumors, such growth was quite cellular with scattered 
mitotic figures and scattered tumor giant cells consistent with the original diagnosis of 
anaplastic astrocytoma (Figure 2.2, inset). While some gemistocytic features were noted 





Figure 2.1. Characteristic histological and genetic features of the IDH1 (R132H) 
anaplastic astrocytoma model. (A) H&E sections of the primary tumor and subsequent 
flank xenografts show histopathological similarity to the original tumor including a 
typical astrocytic morphology, gemistocytic cells and mitotic figures. (B) 
Immunohistochemical staining specific for the IDH1 (R132H) mutant protein shows 
robust staining in the original tumor and all subsequent xenografts. (C) Sequencing of 
exon 4 of IDH1 shows an initial heterozygous G/A mutation in the original patient tumor 
which converts to a hemizygous genotype when the wild type copy is lost in the 













Figure 2.2. Infiltrative growth pattern of orthotopically implanted JHH-273. 
Sections of orthotopically implanted tumor stained with H&E (left) or by 
immunohistochemistry using an IDH1 (R132H) specific antibody (right) to show diffuse 
infiltrative growth pattern in vivo. Below, higher magnification sections show 
histopathological similarity including a typical astrocytic morphology with gemistocytic 
cells and mitotic figures (inset).  
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IDH1 mutant model grows in vivo as flank and orthotopic tumors but not in vitro 
 The IDH1 mutant xenograft grew rapidly in both the flank and at orthotopic sites 
(Figure 2.3).  Serially transplantable flank xenografts reached maximum size (2.0 cm3) 
approximately 7 weeks after implantation and grew as dense, localized, hypercellular 
masses. Attempts to expand freshly disassociated flank tumor in vitro were unsuccessful, 
despite relatively high viability following disassociation. Since growth was observed in 
vivo but not in vitro, it is possible that there may exist a synergy between host 
environment and tumor cell culture. For this reason, co-culture was attempted using 
lethally irradiated mouse embryonic feeder cell in serum-free medium. However this was 
also unsuccessful.  
Since in vitro culture was not possible, orthotopic implantation required fresh 
disassociation of flank tumor, in the absence of serum or growth factors. Orthotopically 
implanted tumors maintain robust IDH1 (R132H) expression and a diffuse growth 
pattern, characteristic of anaplastic astrocytomas. Mice lost weight and showed 
neurological deficits approximately 5 weeks following implantation. Median survival 
time for mice bearing intracranial tumors was 63 days following implantation. The model 






Figure 2.3. Growth of JHH-273 in vivo (A) Subcutaneously implanted flank xenografts 
grow to maximum size (2.0 cm3) in approximately 7 weeks. (B) Orthotopically implanted 




JHH-273 produces 2-HG  
 
Production of 2-HG from α-KG is a hallmark of IDH1 mutations and its 
accumulation is believed to underlie the pathogenesis of IDH1 mutations. Therefore, we 
investigated whether our patient-derived model produces 2-HG. LC/MS analysis was 
performed on snap frozen tissue from well-established flank xenograft (passage 7). JHH-
273 produced high levels of 2-HG which correspond to the endogenous levels reported in 
IDH1/2 mutant gliomas (Figure 2.4). In contrast, 2-HG was nearly undetectable in tissue 






Figure 2.4. 2-HG production in JHH-273. IDH mutant xenograft produces high levels 




Whole exome sequencing reveals mutations in TP53, ATRX, and deletion of 
CDKN2A 
To more completely characterize our IDH1 mutant model, we performed whole 
exome capture and next-generation sequencing on gDNA obtained from flank xenograft 
tissue. Although matched control DNA was not available for analysis, we utilized gDNA 
derived from the whole blood of two unrelated individuals as well as the dbSNP database 
to remove common SNPs. We achieved a mean coverage of 124x across the exome, with 
94% covered by at least 10x. Copy number variation (CNV) analysis revealed deletion of 
genetic content at multiple points throughout the genome, resulting in a loss of 39 known 
genes and including a 1.3 Mb deletion in chromosome 9. No genetic amplifications were 
observed.  After removal of common SNPs, our analysis revealed 231 candidate somatic 
mutations in 170 genes. These mutations consisted of missense (83.1%), frameshift 
(7.4% ), splice site (3.0%),  nonsense (0.9% ), and insertions/deletions (5.6%).  
Promising candidate mutations were selected based on a comprehensive list of 
known driver gene mutations [59]. Of the 125 published Mut-driver genes, five were 
present in the IDH1 (R132H) model. Exome sequencing confirmed the known IDH1, and 
additionally revealed missense mutations in TP53, a frameshift mutation in ATRX and 
deletion of CDKN2A (Table 2.1). The frameshift mutation in ATRX is predicted to 
produce an early stop codon, resulting in the loss of 81% of the protein. Concurrent 
mutations in TP53, IDH1, CDKN2A and ATRX have been well reported in multiple 
anaplastic astrocytoma samples and have been used as genetic signatures in the 
classification of glioma. Whole exome sequencing thus demonstrated that our IDH1 
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Table 2.1. Genetic Mutations in JHH-273 
 
Gene Symbol Genetic Mutation Mutation Type Protein Mutation 
ATRX T1635X Frameshift Nonsense 
CDKN2A N/A Deletion N/A 
IDH1 G395A Missense R132H 
TP53 C736T Missense E246L 




Model exhibits Alternative Lengthening of Telomeres (ALT) 
Due to the association of ATRX mutations with the alternative lengthening of 
telomeres phenotype, telomere length was assessed by telomere specific fluorescent in 
situ hybridization (FISH) in primary tumor, and in flank and orthotopic xenografts. An 
ALT positive phenotype was identified by the presence of large ultra-bright telomeric 
FISH foci in a subset of tumor cells [60]. The primary patient tumor exhibited ALT-
associated foci (Figure 2.5A), which was robustly maintained in the flank and orthotopic 
xenografts (Figure 2.5B and C, respectively). Interestingly, although the original patient 
sample showed ALT-associated foci only in a subset of the tumor cells, the flank and 
orthotopic xenograft had a more homogenous pattern, with nearly every cell being 
positive for ALT-associated foci. In contrast, the ALT phenotype was not present in an 










Figure 2.5. ALT characterization in JHH-273. (A) Telomere-specific FISH analysis in 
the original patient tumor, (B) the flank xenograft tumor (C) and the orthotopically 
implanted tumor show a strongly ALT positive phenotype, as indicated by large, 




In this work, we characterize the first in vivo model of a patient-derived IDH1 
mutant anaplastic astrocytoma, JHH-273, which was originally reported in a preclinical 
drug study earlier this year. The model was established after many attempts in order to 
enhance translational studies with more accurate in vivo models. Prior work from our 
laboratory showed that the JHH-273 model maintains the IDH1 mutation after serial 
passage, produces 2-hydroxyglutarate in vivo, and bears a hypermethylated phenotype 
characteristic of IDH1 mutant gliomas [61]. Further genetic sequencing revealed that the 
JHH-273 model harbors mutations in TP53, CDKN2A and ATRX, and exhibits the ALT 
telomere maintenance phenotype. The JHH-273 model maintains infiltrative intracranial 
growth with a consistent time to death, making it the only practically usable animal 
model for IDH1-mutant anaplastic astrocytoma. This model represents the only 
documented IDH1-mutant anaplastic astrocytoma model with ALT, and only the third 
documented glioma model with ALT, making this model useful for preclinical studies 
targeting the ALT pathway [60, 62]. Collectively this data suggests that the patient 
derived JHH-273 model is characteristic of an IDH1 mutant anaplastic astrocytoma and 
represents a valuable tool for preclinical testing of compounds targeting IDH1 mutations 








5-AZACYTIDINE REDUCES METHYLATION, PROMOTES DIFFERENTIATION 
AND INDUCES TUMOR REGRESSION IN A PATIENT-DERIVED IDH1 MUTANT 
GLIOMA XENOGRAFT 
Introduction 
Abnormal DNA hypermethylation has been recognized as a possible target in 
cancer and DNA methylation reducing drugs, including 5-azacytidine that was reported 
nearly 40 years ago [63]. 5-azacytidine is an analogue of cytidine and it is incorporated 
into DNA and RNA. At therapeutic doses, 5-azacytidine inhibits DNA methyltransferase 
leading to a reduction in DNA methylation. In particular, 5-azacytidine is a potent 
inhibitor of DNA methyltransferase 1 (DNMT1), inducing ubiquitin-dependent 
degradation of the protein [64]. 
Unfortunately, despite the growing understanding of IDH1/2-mutant gliomas, the 
development of effective therapies has proved challenging. IDH1/2- mutant tumors do 
not adapt to growth in culture and endogenous mutant models remain scarce [53, 65].  
Engineered cell lines have been useful in elucidating the complex network underlying 
IDH1/2 mutations but lack the appropriate genetic and mutational context, as well as the 
microenvironmental context, found in patient derived IDH1/2-mutant gliomas. Patient 
derived endogenous IDH1/2-mutant models are therefore critical for the development and 
testing of therapies which target IDH oncogene-driven pathways and mechanisms.   
Here we report preclinical demonstration of efficacy and mechanism of 5-
azacytidine in our anaplastic astrocytoma model (Chapter 2).  Long term administration 
of 5-azacytidine resulted in inhibition of DNMT1, loss of methylation of key genomic 
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markers, in vivo induction of differentiation, reduction of cell proliferation  and 
significantly reduced tumor growth. Tumor growth was essentially arrested at 14 weeks 
and subsequently showed no signs yet of re-growth after withdrawal of therapy.   
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Materials and Methods 
Flank xenograft establishment and passage 
A fresh tissue sample was obtained during the resection of an anaplastic 
astrocytoma (WHO grade III) from a male patient as described in Chapter 2.  
 
Sequencing of IDH1  
DNA isolation and sequencing of IDH1 exon 4 was performed as described in 
Chapter 2.  
 
Histology and Immunohistochemistry 
Histology and immunostaining was performed as described in Chapter 2.   
 
Pyrosequencing of target genes 
Bisulfite conversion was carried out using EpiTect Bisulfite Kit (Qiagen, CA) 
with 1μg genomic DNA. PCR was carried out using PyroMark PCR kit (Qiagen, CA) 
following the manufacturer's instructions. The samples were run in a 25 µL reaction with 
2.5 µL of primer reconstituted according to manufacturer’s instructions. The 
thermocycler conditions are an initial activation step of 95ºC for 15 minutes, 45 cycles of 
94ºC for 30 seconds, 56ºC for 30 seconds, and 72ºC for 30 seconds, and a final extension 
of 72ºC for 10 minutes. Controls included 100%, 50%, and 0% human methylated control 
DNA (Zymo Research Corp, CA), and a no-template control. Samples plus controls were 
amplified using primer kits Hs_PYCARD_03_PM, Hs_RBP1_02_PM, 
Hs_MGMT_01_PM, Hs_SOX9_08_PM, and Hs_BMP4_02_PM. Amplified DNA was 
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then pyrosequenced using the PyroMark CpG Assay kit (Qiagen, CA) on the PyroMark 
24 system (Qiagen, CA). Bisulfite conversion, PCR amplification and pyrosequencing 
was performed at the Genetic Resources Core Facility, Johns Hopkins Institute of 
Genetic Medicine, Baltimore, MD. 
 
Therapeutic administration of 5-azacytidine to JHH-273 flank bearing mice 
Female, athymic nude mice aged 4-6 weeks were implanted with the JHH-273 
tumor line as described above. Five days after implantation, mice received daily i.p. 
injections of 5-azacytidine (Sigma Aldrich, MO; 3 mg/kg) diluted in sterile water for five 
days followed by a two day rest period. Treatment continued until tumors reached 
maximum allowable size. Following sacrifice, tumors were harvested and passaged 
individually into another set of female athymic nude mice, identically as before. 5-
azacytidine treatment was resumed immediately after tumor implantation and continued 
until tumors reached maximum allowable size (Cycle 2). Following the second cycle of 
treatment, tumors were again resected and passaged into two groups of mice. To assess 
the durability of the therapeutic response, 5-azacytidine treatment was withdrawn in one 
group of pre-treated animals and resumed immediately in the other. Treatment strategy is 
outlined in Figure 4. Tumors were measured weekly and volume was calculated as: 
H×L×W (mm3).  
 
Immunoblotting 
Protein lysates were prepared using RIPA buffer and immunoblot analysis was 
performed as previously described [66].  Briefly, protein lysates were obtained from 
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freshly resected flank tumors using RIPA buffer (ThermoScientific, MA) containing Halt 
protease inhibitor cocktails (Pierce, IL) according to the recommendations of the 
manufacturer. Lysates (50 μg) were heated to 95°C in Laemmli sample buffer for 10 min 
and separated on SDS polyacrylamide gels. Proteins were transferred to polyvinylidene 
fluoride membranes (Bio-Rad) in Western transfer buffer [25 mmol/L Tris (pH 8.3), 192 
mmol/L glycine, and 20% methanol]. For Western blot analysis, membranes were 
blocked for 1 h at room temperature in 5% nonfat dry milk in TBST (1× TBS, 0.1% 
Tween 20) and incubated overnight at 4°C with antibodies against GFAP (Cell Signaling 
Technology, MA), or DNMT1 (New England Biolabs, MA). After washing, membranes 
were incubated with a horseradish peroxidase-linked goat anti-rabbit antibody for 1 h at 
room temperature. Antibody detection was achieved by chemiluminescence according to 
the manufacturer's recommendations (Pierce, IL). 
 
Statistical analysis 
Statistical analyses were performed using a student t-test for comparisons between 




JHH-273 CpG hypermethylation and by 5-azacytidine treatment in vivo 
Recent data has shown that one consequence of IDH mutation is the induction of 
global DNA hypermethylation that is believed to contribute to tumor formation and 
maintenance [45, 52, 67, 68]. In order to determine the methylation status JHH-273, we 
performed pyrosequencing analysis of bisulfate-converted genomic DNA at five genetic 
loci. This technique allows the identification of bases that are methylated in vivo 
(reference).  Targets were selected based on the reported frequency of hypermethylation 
in IDH1 (R132H) primary tissue and engineered cell systems as well as their known 
functional impact in tumoriogenesis or tumor maintenance [37, 45, 68-76]. The analysis 
was performed using genomic DNA obtained from both early and late passage xenograft 
tissue (passages 1, 7 and 10) as well as two unrelated IDH1 (R132H) anaplastic 
astrocytoma samples and three IDH1 (WT) glioma primary patient samples as controls.   
The original patient tumor exhibited high degrees of CpG methylation at four of 
the five loci, which was maintained in the xenograft tissue at all passages analyzed 
(Figure 3.1A). The high levels of CpG methylation were consistent with other primary 
patient IDH1 (R132H) anaplastic astrocytoma samples. In contrast, wild type IDH1 
gliomas exhibited low levels of methylation at all targets analyzed, consistent with 
reported data. Of note, although SOX9 hypermethylation in IDH mutant gliomas has been 
reported in several studies, we did not detect significant methylation in either primary 
tissue sample or xenograft. Overall, JHH-273 reflected the hypermethylated genomic 
landscape of the original patient tumor and exhibited the characteristics of an IDH1 
(R132H) anaplastic astrocytoma.  
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To determine whether the hypomethylating agent 5-azacytidine was able to 
reverse methylation of the JHH-273 tumors in vivo, we analyzed CpG methylation of 
flank tumors following treatment with one cycle of 5-azacytidine (1 mg/kg and 5 mg/kg). 
5-azacytidine was able to substantially reduce CpG hypermethylation at four of the five 
targets analyzed in a dose specific manner (Figure 3.1B). Although a significant tumor 
regression was observed in the high dose treatment group, this dose was associated with 





Figure 3.1. JHH-273 shows characteristic DNA hypermethylation which can be 
reversed with 5-azacytidine treatment in vivo. (A) Pyrosequencing shows that the 
original patient tumor exhibits high levels of DNA methylation in several target genes. 
This hypermethylated phenotype is maintained in the xenograft and is characteristic of 
IDH1 mutant gliomas. In contrast, IDH1 wild type glioma is not hypermethylated. (B) 5-
azacytidine treatment for 1 cycle reverses methylation at several targets in a dose specific 





Long term treatment with 5-azacytidine reduces tumor growth in an IDH1 mutant 
model 
 
To extend the relative exposure time of JHH-273 tumor to 5-azacytidine, serial 
passage of flank tumors from treated mice was performed using the strategy outlined in 
Figure 3.2. A moderate reduction of tumor burden was observed within one treatment 
cycle, but this decrease was not statistically significant (p=0.27) (Figure 3.5A). Following 
passage of 5-azacytidine treated flank tumors, a second cycle of treatment with the 5-
azacytidine was continued until maximum tumor burden was reached. 5-azacytidine 
significantly reduced tumor burden by the fourth week of Cycle 2 (p<0.01). This 
difference between untreated and treated tumors increased throughout the treatment 
period (Figure 3.3B). During passage of tumor after Cycle 2, the tissue was found to be 
unusually firm and encapsulated by gelatinous tissue.  Enzymatically disassociated 
fractions of the tumor were found to contain fewer than 10% viable cells, by Trypan blue 
exclusion. 
5-azacytidine serially treated tumors were implanted for a third time into two 
groups of athymic nude mice (Cycle 3). To assess the durability of the therapeutic 
response, treatment was withdrawn in one group. Significant tumor regression was 
observed in both groups, including the treatment withdrawn group, suggesting a durable 
therapeutic response of 5-azacytidine (Figure 3.3C).  
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Figure 3.2. Treatment strategy for 5-azacytidine in the IDH1 mutant flank model. 
Flank tumors were treated with 5-azacytidine until maximum tumor size was reached 
(Cycle 1). In order to extend the relative time of treatment, the flank tumors were 
individually passaged and 5-azacytidine treatment resumed immediately following 
implantation (Cycle 2). Tumor passaging was repeated a third time into two groups, one 
which immediately resumed 5-azacytidine treatment or one which had treatment 






Figure 3.3. Long term treatment with 5-azacytidine reduces tumor growth in an 
IDH1 mutant model. (A) Mice bearing IDH1 mutant flank tumors and treated with 5-
azacytidine show a reduction in tumor burden (p=0.27)  (B) Cycle 2 of 5-azacytidine 
treatment significantly reduces tumor growth compared to untreated tumors (C) Pre-
treatment with 5-azacytidine significantly decreases tumor growth, even after treatment is 
withdrawn. Cycles 1 and 2: Five mice (10 tumors) per group, Cycle 3: Four mice (4 
tumors) per group. * p<0.01, Error bars=SEM 
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Treatment with 5-azacytidine induces differentiation and reduces the proliferative 
index  
Intracellular 5-azacytidine activity was confirmed by DNMT1 expression in tissue 
from untreated and 5-azacytidine treated tumors (Cycles 1 and 2). DNMT1 is expressed 
at high levels in untreated tumors but expression of the protein is robustly inhibited 
following treatment with 5-azacytidine. DNMT1 protein was undetectable after one 
treatment cycle of 5-azacytidine (Figure 3.4A).  
Prior studies had proposed that the IDH mutation inhibits DNA and histone 
demethylation, leading to a block in cellular differentiation [69]. Additionally in a study 
published in this issue, treatment of endogenous IDH1 mutant glioma cell lines with 
hypomethylating agent 5-aza-2'-deoxycytidine was found to drive differentiation in vitro 
[67]. To test whether reduction of hypermethylation by 5-azacytidine leads to an increase 
in cellular differentiation in vivo, immunoblotting was performed for glial fibrillary acidic 
protein (GFAP) in tumors treated with 5-azacytidine. GFAP expression was undetectable 
in the untreated tumors, confirming the undifferentiated phenotype of IDH (R132H) 
tumors.  Following one cycle of 5-azacytidine treatment, GFAP expression was robustly 
increased and protein levels were maintained throughout the second treatment cycle. To 
validate these findings, immunohistochemical analysis was performed on formalin fixed 
paraffin embedded tissue. Compared with untreated tissue, 5-azacytidine treatment 
markedly increased the fraction of GFAP-positive cells (Figure 3.4B, 3.5A). These 
results confirm that IDH mutations plays an active role in repressing cellular 
differentiation, a deficiency which is reversible with long term treatment with 
hypomethylating agent 5-azacytidine.  
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To test whether 5-azacytidine-induced differentiation translated to a decrease in 
proliferation, tumors from 5-azacytidine treated mice were stained with the proliferation 
marker Ki-67.  5-azacytidine treatment significantly reduced the fraction of Ki-67 
positive cells in a time dependent manner, with the greatest decrease in proliferation 


















Figure 3.4. Treatment with 5-azacytidine induces differentiation in an in vivo IDH1 
(R132H) glioma model. (A) 5-azacytidine treatment causes loss of DNMT1 expression 
in vivo following one treatment cycle. (B) GFAP expression is restored following one 






Figure 3.5. Treatment with 5-azacytidine induces differentiation and reduces the 
proliferative index in an in vivo IDH1 (R132H) glioma model. (A) 
Immunohistological staining of GFAP shows significant increase of protein expression in 
the cytoplasm of 5-azacytidine treated cells (B) Ki67 staining shows a decrease in the 













Somatic mutations in IDH1 and IDH2 are found in a high percentage of low grade 
and progressive gliomas. IDH mutant gliomas are associated with a pro-neural gene 
expression profile, a characteristic pattern of DNA hypermethylation and a signature of 
repressive histone methylation [52].  It is believed that the 2-HG produced by IDH-
mutant proteins promote tumorigenesis by blocking cellular differentiation via 
hypermethylation of tumor suppressor genes involved in differentiation [44-46, 52, 68].   
The current therapy for low grade gliomas is surgical resection followed by 
monitoring with periodic MRI scans. Unfortunately, most of these tumors recur or 
progress to high grade gliomas. If the gliomas progress to high grade no curative therapy 
is available, although repeat surgery and additional treatment with radiation can 
temporarily slow tumor growth. Median survival for grade II astrocytoma (fibrillary or 
diffuse astrocytoma) is approximately 5 to 7 years and for grade III astrocytoma 
(anaplastic), median survival is 4 to 5 years [77]. New therapies are urgently needed. 
In this work, we report the first in vivo model of a patient derived IDH mutant 
anaplastic astrocytoma, JHH-273.  This model was established after many attempts, 
which underscores the difficulty most labs have had at growing IDH mutant 
astrocytomas. The goal of establishing the xenografts was to enhance translational studies 
with more accurate models harboring relevant mutations that developed during the course 
of human tumorigenesis. Importantly, we show in that IDH1 (R132H) expression is 
stable through multiple passages, 2-HG is robustly produced, and the model bears a 
hypermethylated CpG phenotype characteristic of an IDH1 mutant glioma.   
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Once evidence emerged that hypermethylation was a likely oncogenic mechanism 
of IDH mutations, demethylating agents became an attractive choice for translational 
investigation. When 5-azacytidine treatment was first tested in the JHH-273 model, a 
decrease in methylation was observed in a dose specific manner but was associated with 
only marginal reduction of tumor burden. We were able to achieve a significant in vivo 
response by lowering drug dosing and extending the relative exposure time of tumor to 
drug by passaging pre-treated tumor tissue into treatment naïve mice.  
Short term 5-azacytidine treatment (1 cycle, 7 weeks) perhaps started to slow 
tumor growth, but by doubling the treatment time, we were able to achieve tumor 
regression. Treatment with 5-azacytidine for 2 cycles elicited a durable treatment 
response, as treatment withdrawal for an additional 6 weeks did not produce any visible 
signs of tumor re-growth (although we continue to monitor the mice). At the end of 2 
treatment cycles, the tumors had changed dramatically in appearance with the presence of 
hard fibrous tissue and less than 10% cell viability. Additionally, with 7 weeks of 
treatment 5-azacytidine drives cellular differentiation to the astrocytic linage as seen by 
increase in GFAP expression, further underscoring the reversal of the presumed 
mechanism of mutant IDH1 oncogenesis. These data are consistent with the hypothesis 
that demethylating drugs may promote re-expression of previously silenced Polycomb 
controlled genes and subsequently activate genes involved in differentiation [45, 78]. 
The observed induction of cellular differentiation and subsequent reduction in 
proliferation following treatment with a hypomethylating agent in IDH mutant glioma is 
surprisingly consistent with an independent study that was simultaneously reported [67]. 
In this companion work, decitabine, a closely related demethylating agent, was found to 
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preferentially induce differentiation in IDH mutant glioma cells but not in wild type cells. 
This work showed very similar mechanistic results to this study, and since both the drug 
and the models utilized are independent, the collective evidence supports the hypothesis 
that the gene expression reactivated by demethylating agents is sufficient to produce 
terminal differentiation in the self-renewing malignant cells of the tumor.  
  5-azacytidine is currently FDA approved for the treatment of myelodysplastic 
syndrome and well tolerated in patients. Its close structural analogue, decitabine, can 
effectively cross the blood brain barrier in laboratory animals [79]. Experimentally, pre-
treatment of cells with transient, low dose exposure of 5-azacytidine to has been shown to 
decrease tumorigenicity and percentage of stem-like cells in several cancer models [80]. 
In addition to considering 5-azacytidine or decitabine for recurrent or high grade IDH 
mutant glioma, 5-azacytidine therapy may also be useful as a maintenance therapy 
following tumor resection. Due to the infiltrative growth pattern of astrocytoma, 
complete resection is nearly impossible and the remaining tumor frequently recurs, often 
as a higher grade glioma. Low-dose treatment with 5-azacytidine following resection may 
drive the remaining mutant IDH glioma cells into differentiation, thereby delaying 
recurrence.   
 This work supports the further investigation of demethylating drugs such as 5-
azacytidine for its use against mutant IDH1 gliomas both in the laboratory and in clinical 
trials. Although it is very likely that these drugs have the potential to help patients with 
IDH1 mutant gliomas,  the optimal demethylating drug, patient population, dosing 
strategy, delivery and drug combinations have yet to be determined.   
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CHAPTER 4 
FUTURE DIRECTIONS OF 5-AZACYTIDINE THERAPY FOR IDH1 MUTANT 
GLIOMAS 
 
We have demonstrated tumor regression in our novel IDH1 mutant model using 
the DNA methyltransferase 1(DNMT1) inhibitor 5-azacytidine (5-aza). The success of 
this strategy relied on the knowledge that IDH1 mutant gliomas exhibit a phenotype of 
globally hypermethylated DNA and chromatin. 5-azacytidine is currently an FDA 
approved drug for the treatment of myelodysplastic syndrome and is well tolerated in 
patients. Its close structural analogue, decitabine (DAC, 5-aza-2’deoxyazacytidine) has 
been shown to be effective at slowing tumor growth in IDH1 mutant oligodendroglioma 
models [79]. Experimentally, pre-treatment of cells with transient, low dose exposure of 
5-azacytidine has been shown to decrease tumorigenicity and percentage of stem-like 
cells in several cancer models [80]. Although it is very likely that these drugs have the 
potential to help patients with IDH1 mutant gliomas,  the optimal demethylating drug, 
patient population, dosing strategy, delivery for intracranial tumors and drug 
combinations have yet to be determined.  
 
Determine intracranial accumulation of 2-deoxy-5-azacytidine and 5-azacytidine in 
the orthotopic model.  
Studies have shown that 2-deoxy-5-azacytidine (DAC) has the ability to cross the 
blood-brain barrier and can accumulate in the cerebrospinal fluid up to half of its plasma 
concentration after drug infusion in dogs and rabbits [79]. However, the intracranial 
accumulation of 5-aza is not yet known. To determine intracranial accumulation of 5-aza, 
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non-tumor bearing mice were injected with 5-aza (3mg/kg) for 3 days upon which time 
the brains were harvested and snap frozen. Preliminary LC/MS optimization assays of the 
homogenized brains detected 5-aza at a concentration of approximately 0.5-0.8 ng/mg of 
tissue, although validation of these values will be necessary to determine precise 
intracranial concentrations.  Additionally, the blood brain barrier is frequently 
compromised in cases of malignant glioma increasing the likelihood that these 
therapeutic compounds reach the target site. However, the intracranial accumulation of 
DAC and 5-aza has not yet been determined in tumor bearing animals. For this reason, it 
will be of clinical value to repeat this experiment using numerous concentrations of 5-aza 
and DAC to determine intracranial, intratumoral and plasma concentration at multiple 
points following injection. A standard curve can then be used to quantify the levels of 
drug in the brain to assess whether therapeutic levels can be obtained intracranially.  
 
 
Compare single agent efficacy of 2-deoxy-5-azacytidine and 5-azacytidine on the 
reduction of tumor burden and in orthotopic models.  
Preliminary data from our laboratory suggests that pretreatment with 
demethylation therapy significantly extends the survival of intracranially implanted IDH1 
















Figure 4.1. Pretreatment of IDH1 mutant cells with 5-azacyitdine extends 
survival in orthotopically implanted tumors.  Mice bearing flank tumors were 
treated with 5-Aza (3mg/kg) until maximum tumor size was reached. The flank 
tumors were disassociated and implanted intracranially. Treatment with 5-aza was 
resumed until the time of death. Pretreatment of tumors with 5-aza significantly 
extends survival compared to control mice and 5-aza treated mice which were 
bearing untreated tumors. 
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In this experiment, mice bearing flank tumors were treated with vehicle or 5-aza 
(3 mg/kg) until maximum tumor size was reached. The tumors were then resected and 
disassociated into single cell suspensions. The vehicle treated cells were implanted 
intracranially into two groups of mice, one which received then vehicle control and the 
other received 5-aza treatment (3 mg/kg). The 5-aza pretreated cells obtained from the 
flank tumors were implanted intracranially into a third group of mice which then received 
continued 5-aza treatment (3 mg/kg). When implanted intracranially, pretreatment of the 
IDH1 mutant tumors significantly extended survival compared to the non-pretreated 
tumor and suggests that demethylation therapy may reprogram the epigenome to slow 
tumor growth. Although 5-aza alone did not extend survival in non-pretreated tumors, 
this is likely because the tumors grow too rapidly for a treatment effect, as is the case in 
the flank model. A slower growing IDH1 mutant cell line will be necessary to determine 
the single agent efficacy of demethylating agents in non-pre-treated tumors. At the time 
of writing, we are currently conducting this experiment using the IDH1 mutant 
oligoastrocytoma line BT142, a slower growing tumor which has a median survival of 
approximately 100 days [53]. Following implantation, mice are being treated with i.p. 
injections of 5-aza (2 mg/kg), DAC (0.5 mg/kg) or vehicle (saline). If one of the 
demethylating agents is successful in extending survival, we will then use an IDH1 wild 
type glioma neurosphere line, developed in our laboratory, as a control to ascertain the 
specificity of the drug response to the IDH1 mutation [55].  
Although DAC is only approved for I.V. administration, 5-aza is approved in both 
subcutaneous and I.V. forms and in Phase III trials for oral administration.  Additionally, 
there is now an approved generic for the subcutaneous 5-aza. For the drug which exhibits 
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the greatest extension of survival, it will be of clinical value to test all approved forms to 
determine the most effective mode of administration in vivo. 
 
Optimize demethylation therapy with current standard of care 
  Following primary tumor resection, the current available therapeutic options 
include ionizing radiation and oral administration of the DNA alkylating agent 
temozolomide (Temodar, TMZ). It has been found that methylation of the DNA repair 
gene O-6-methylguanine-DNA methyltransferase (MGMT) sensitizes tumors to killing by 
TMZ [81]. In order to determine whether demethylating agents would interfere with 
TMZ sensitization due to MGMT demethylation, mice bearing JHH-273 IDH1 mutant 
flank tumors were treated with 5-aza or vehicle control until maximum tumor size was 
reached. Tumors were passaged to the flanks of mice, which subsequently received TMZ 
(50 mg/kg, 5 days). This data suggests that pretreatment of IDH1 mutant tumors with 
demethylating agent 5-aza does not alter sensitivity to TMZ (Figure 4.2). However, this 
data will need to be validated in the JHH-273 intracranial model and in additional models 

























Figure 4.2. 5-azacytidine pretreated tumors retain TMZ sensitivity in vivo. 
Mice bearing flank tumors were treated with 5-azacytidine (3mg/kg, 7 weeks) or 
vehicle control. 5-aza and vehicle treated tumors were passaged into the flanks of 
mice which were then treated with TMZ (50 mg/kg, 5 days) or with 5-azacyitinde. 
5-azacytidine pretreated tumors retain sensitivity to TMZ.  Error bars=SEM 
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Alterations in DNA methylation and chromatin structure by treatment with 
chromatin modifying agents or transfection with hypermethylated DNA fragments have 
been known to alter radiosensitivity of cells [82]. In a recent study, pre-treatment of the 
IDH1 wild type U373MG glioblastoma cell line with DAC for 18 hours induced 
radiosensitivity compared to cells exposed to radiation alone [82, 83]. It will therefore be 
important to assess whether DNA demethylation will interfere or enhance ionizing 
radiation therapy in IDH1 mutant gliomas in vivo. To conduct this experiment, a small 
animal irradiator may be used to provide 10 grays of localized radiation total over a 
period of 5 days (2 gy x 5). Mice bearing JHH-273 flank tumors will receive 5-aza (3 
mg/kg) or vehicle until maximum tumor size is reached. Tumors will then be passaged to 
the flanks of mice, which will then receive localized radiation and tumor growth 
monitored by caliper volume measurements. Collectively, these experiments will greatly 
inform clinical trials by allowing us to determine the appropriate timing of demethylation 
therapy to the current standard of care.  
 
Determine synergistic combinations with IDH1 Mutant Enzyme Inhibitors 
Since the discovery of mutant IDH1 as an oncogene, the development of IDH1 
inhibitors has been intensely perused in industry and in academia. One such molecule, 
AGI-5198 (Agios, MA) was identified by a high throughput enzymatic screen and found 
to potently inhibit the mutant enzyme and reduce 2-HG levels [84]. This inhibitor was 
able to induce demethylation of histone H3K9me3 and modestly increase expression of 
genes associated with differentiation. Although the reduction in tumor burden and DNA 
methylation was modest[67], combination with DNA demethylating agents is likely to 
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have a synergistic effect by allowing simultaneous reversal of pathogenic 
hypermethylation and suppression of further methylation by blocking 2-HG production.  
Although the AGI-5198 compound is the only published mutant enzyme inhibitor, 
we are currently in negotiations with several pharmaceutical companies 
(GlaxoSmithKline, Novartis) and intend to accumulate (or synthesize from the patent 
literature) as many inhibitors as possible for testing in vivo. Because the blood brain 
barrier permeability of IDH1-mutant enzyme inhibitors is not yet known, it will be vital 
to determine single agent efficacy of mutant IDH1 enzyme inhibitors and combinations 
with DNA demethylating agents in both the flank and orthotopic model.  
 
Combination therapy with HDAC inhibitors  
Due to the widespread epigenetic aberrations in IDH1-mutant glioma, modulation 
of additional epigenetic targets is likely to synergize with demethylation therapy (Figure 
4.3). Widespread increases in repressive histone methylation occur in IDH1 mutant 
gliomas due to the inhibition of JmjC domain containing histone demethylases by 2-HG 
[42]. This increase in repressive histone methylation in IDH1 mutants is followed by 
reduction of activating marks of histone acetylation [52], leading to transcriptional 
repression. Several histone deacetylase inhibitors (HDAC) and histone demethylase 
inhibitors have been developed, most of which are in clinical trials with two obtaining 
FDA approval for myeloma and lymphoma. Although these compounds exhibit single 
agent efficacy, substantial synergy has been found between DNA demethylating and 
histone modulating agents in multiple models [85-88].  
 63 
 Because IDH1 mutant tumors exhibit reduced DNA acetylation and increased 
histone methylation, targeting each of these is likely have synergy with DNA 
demethylating agents in vivo. Vorinostat (SAHA) is the first HDAC inhibitor to gain 
FDA approval and is currently for the treatment of cutaneous T cell lymphoma. Recently, 
SAHA has shown synergy with decitabine to induce autophagy and inhibit cell growth in 
an ovarian xenograft model [89]. The combination of SAHA with 5-aza or DAC is 
currently in multiple clinical trials and the combination has shown strong activity in a 
Phase I trial of newly diagnosed cases of MDS or acute myelogenous leukemia and Phase 
II trials are currently underway [90].  
Next generation HDAC inhibitors such as entinostat (MS-275) show additional 
promise for neoplastic malignancies with entinostat currently in  phase II trials for 
Hodgkin’s lymphoma, breast and lung cancer. Interestingly, entinostat was found to 
exhibit synergy is 5-azacytidine in an orthotopic model of lung adenocarcinma, leading to 
a reduction of tumor burden and re-expression of Polycomb regulated genes [91]. In 
clinical trials, the combination of entinostat and 5-aza was shown to have significant 
activity in relapsed non-small cell lung cancer [92]. We have found that the MS-275 is 
well tolerated in our IDH1 mutant model and hypothesize that combinations of vorinostat 
or entinostat with DNA demethylation therapies (5-aza or DAC) will be synergistic in 
IDH1 mutant gliomas due to the widespread epigenetic changes, both DNA and histone, 









Figure 4.3. Targeting epigenetic reprogramming caused by oncometabolite 2-HG. 
Mutation in IDH1 leads to the accumulation of the oncometabolite 2-HG. 
Accumulation inhibits the TET family of enzymes believed to be involved in DNA 
demethylation and histone lysine demethylases. Targeting multiple components 
involved in epigenetic modification may lead to a synergistic effect in vivo.  
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Combination therapy with LSD1 inhibitors  
In addition to a reduction of histone acetylation, histone methylation is 
significantly increased in IDH1 mutant gliomas. Lysine (K)-specific demethylase 1A 
(LSD1), a histone demethylase, is able to remove methylation marks H3K4me2 and 
H3K9me2. Studies have shown that increasing promoter H3K4me2 is associated with 
increasing levels of active gene transcription [93, 94]. Because LSD1 therefore has the 
capacity to repress gene expression at these areas, several novel LSD1 inhibitors have 
been developed which show single agent efficacy [95, 96]. Of most significance, the 
LSD1 inhibitors 2D and PG144 have both shown synergy with 5-azacytidine in an in vivo 
xenograft model of colorectal cancer [96]. This significant reduction of tumor burden was 
accompanied by increased H3K4 methylation and re-expression of silenced genes.  
Newly synthesized LSD1 inhibitors (2D, BP-107-15) are likely to exhibit synergize with 
DNA demethylating agents in IDH1 mutant glioma by increasing the active histone 
markers H3K4me2 and H3K9me2 while simultaneously reducing repressive DNA 
methylation marks. At the time of writing, we are currently utilizing the flank JHH-273 
model to determine the efficacy of combinatorial therapy of 5-aza and LSD1 inhibitors 
2D and BP-107-15 on reduction of tumor burden. The single agent or combination that is 
most effective at reducing tumor burden will be validated in the JHH-273 orthotopic 
model and the BT142 IDH1 mutant oligoastrocytoma orthotopic model. Additionally, the 
specificity of drug effect to IDH1 mutant gliomas will be tested by repeating the study in 





Determine the epigenetic and transcriptional alterations that are most useful for a 
successful therapeutic response 
In order to elucidate which epigenetic and transcriptional alterations are 
responsible for suppression of tumor growth, a rigorous evaluation of the tumors which 
exhibit a successful drug response will be necessary. We are currently examining the full 
methylation and transcriptional profiles of IDH1 mutant tumors treated with 5-aza at 
multiple treatment cycles. Briefly, RNA and gDNA was obtained from the JHH-273 
flank tumors at each treatment cycle. Following bisulfate conversion of gDNA, 
methylation analysis will be performed using the Illumina Infinium 
HumanMethylation450 Beadchip which allows for analysis of >485,000 methylation 
sites. β values for treated tumors will be subtracted from the β values of the tumors 
treated with vehicle control. Any probe with Δβ <-0.4 will be considered to be 
hypomethylated following treatment.  
To further address the functional consequences of epigenetic therapy, we will 
perform global gene expression analysis in flank tumors treated with 5-aza at each 
treatment cycle using a high-density oligonucleotide microarray (Agilent 4x44K Whole 
Human Genome Microarray). Transcriptional alterations will be subjected to Gene Set 
Enrichment Analysis (GSEA) with GSEA software v 2.0.14. We will assess the 
significance of the gene sets with an FDR Q-value cutoff of 25%. The most differentially 
expressed genes will be identified with the “leading edge subset” that consists of genes 
with the most contribution to the enrichment score of a particular gene set [97].  
Knowledge of both transcriptional and epigenetic changes will allow us to integrate the 
two data sets to determine if reductions in gene methylation translate to increases in gene 
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transcription. To do this, we will first use an unsupervised variance analysis to assess the 
alterations in global gene expression after treatment. A one-way ANOVA analysis will 
then be performed on the data set to determine which transcripts significantly altered 
following treatment. Finally, we will analyze the two gene sets, consisting of 
hypomethylated and transcriptionally upregulated genes, using the Molecular Signature 
Database (MsigDB) to determine whether there is any overlap with curated gene sets. 
Additionally, we will employ gene ontology analyses for biological processes and 
molecular function using the DAVID bioinformatics resource [67].  
This experimental strategy will allow us to correlate epigenetic and transcriptional 
changes to therapeutic response.  
 
Investigate promising targets of successful therapeutic response.  
In order to determine which pathways and genes are responsible for a therapeutic 
response, we will perform functional genomics studies using in vitro systems. Using the 
methylome and transcriptome data, we will carefully demonstrate which genes are 
responsible for cell growth and differentiation using IDH1 mutant cell lines and 
subsequent in vivo studies. The genetic targets which significantly increase expression 
following a loss of methylation may be involved in suppression of tumor growth and 
induction of cellular differentiation. Because the JHH-273 line is not amenable to cell 
culture, we will use the BT142 IDH1 mutant oligoastrocytoma line for in vitro studies. 
BT142 cells will be transfected with siRNA constructs as well as scrambled siRNA 
controls to determine the consequences on cell proliferation, clonogenicity and capacity 
for differentiation, as described previously [39, 98]. As an additional control, we will use 
 68 
the IDH1 wild type Br23C neurosphere line transfected with identical siRNA constructs. 
This will inform us whether the effects are specific to IDH1 mutant tumors or to gliomas 
as a whole. In vitro studies will then be validated in the in vivo model using intracranial 
implantations of the engineered cell lines. This will allow us to determine whether in 
vitro reductions in proliferation translate to in vivo reductions in tumor growth and 
extension of survival. Collectively the results of this study will allow us to reveal which 
molecular alterations are responsible for the suppression of tumor growth in IDH1 mutant 
glioma. 
 
Determine effect of demethylation therapy on populations of undifferentiated stem-
like cells 
Stem cells rely on tightly controlled regulation of chromatin structure and DNA 
methylation to maintain homeostasis. Studies have shown that treatment of stem cells 
with epigenetic modulating agents induces changes in these cell populations [99].  For 
this reason, it is possible that treatment of the IDH1 mutant gliomas with demethylating 
agents and epigenetic modulators may alter the population of undifferentiated stem-like 
cells, also called tumor initiating cells. In order to determine the effect of epigenetic 
modulation on the population of stem-like cells in the IDH1 mutant tumors, we will use 
look at several putative cancer stem cell markers in those tumors which exhibit the 
strongest therapeutic response. JHH-273 flank tumors will be treated with 5-azacytidine 
for 3 treatment cycles. At the end of the third treatment cycle, flank tumors will be 
disassociated into a single cell suspension, fixed and stained using human specific 
fluorescent antibodies against CD133, Nestin and aldehyde dehydrogenase (ALDH). The 
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cells will them be subjected to flow cytometry analysis in order to quantify the change in 
stem-like cells. After gating for single, live cells populations, the undifferentiated stem-
like cells will be measured as those which stain positive for CD133, Nestin and aldehyde 
dehydrogenase (CD133+/Nestin+/ALDH+). These results will be validated in the 
intracranial model in both the BT142 and the Br23C models using with 
immunohistochemical analysis using formalin fixed paraffin embedded tissue slides from 
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